DEDUCE study demonstrates AUC of 0.86 in overall cohort, including more than 700 prospective samples AUSTIN, Texas, April 13, 2022 /PRNewswire/ — Natera, Inc. (NASDAQ: NTRA), a global leader in cell-free DNA testing, today announced that its clinical validation study1 on its donor-derived cell-free DNA (dd-cfDNA) test for the assessment of acute rejection in heart transplant patients, […]